Project Grant R21HL188907
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $239K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27701, USA
Similar Awards
- The National Heart Lung and Blood Institute awarded Duke University $313,416 on August 15, 2026, to validate a functional assessment tool for sickle cell disease and pilot an exercise and nutrition intervention. The award supports work under the Cardiovascular Diseases Research program (CFDA 93.837). The project will evaluate the validity and reliability of the Sickle Cell Disease Functional Assessment (SCD-FA) in a prospective cohort of adults with SCD aged 18 years and older, with the...
- The National Heart, Lung, and Blood Institute awarded Emory University $797,648 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate red blood cell-bound cell-free DNA as a predictor of acute anemia in sickle cell disease. The research examines whether elevated levels of cell-free DNA released during vaso-occlusive complications in sickle cell disease bind to toll-like receptor 9 (TLR9) on red blood cells, thereby modulating red blood cell clearance...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $171,488 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a nationwide examination of access to comprehensive care in sickle cell disease. The research uses national Medicaid insurance claims data to address two analytic aims. The first aim identifies three groups of people with sickle cell disease—those who do not receive care from a...
- The National Heart, Lung, and Blood Institute awarded Emory University $1,288,327 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on red blood cell survival in recipients with sickle cell disease. The research evaluates the impact of donor and recipient factors on transfused red blood cell (RBC) survival in sickle cell disease patients and examines mechanisms contributing to RBC clearance. The study proposes an experimental,...
- The National Heart, Lung, and Blood Institute awarded the University of Tennessee Health Science Center $253,395 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify genetic modifiers of acute kidney injury in sickle cell disease. The award funds research evaluating candidate genetic variants—apolipoprotein L1 (APOL1), hemeoxygenase-1 (HMOX1), BCL11A, and alpha thalassemia—for their association with acute kidney injury (AKI) in a well-genotyped and...
- The National Heart Lung and Blood Institute awarded $1.449 million to the University of North Carolina at Chapel Hill on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837, R01HL177199) to conduct a multi-site prospective study examining the prevalence, clinical impact, and treatment response of sleep-associated hypoxemia in adults with sickle cell anemia. The study enrolls adult patients with homozygous sickle cell anemia (SCA) at four institutions—University of...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $232,836 on December 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop biomarkers of ischemic risk in adults with sickle cell disease using non-invasive quantitative neuroimaging methods. The research uses arterial spin labeling MRI and other quantitative imaging techniques to test hypotheses regarding cerebral oxygen utilization in patients with sickle cell disease...
- The National Heart, Lung, and Blood Institute awarded $1.834 million to St. Jude Children's Research Hospital Inc. on July 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to test senescence-targeting therapies for improving hematopoietic stem cell function and mobilization in sickle cell disease. The research addresses pathologic bone marrow stress in sickle cell disease patients, which damages and depletes hematopoietic stem and progenitor cells and selects for...
- The National Institute of Neurological Disorders and Stroke awarded Duke University $3.119 million on September 18, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate computational and clinical tools for understanding pain variability in sickle cell disease. The funded work constitutes a prospective cohort study enrolling 1,250 individuals aged 15 years and older living with sickle cell disease in the United States. Over three years, the research...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $873,449 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to evaluate modern pharmacotherapy treatment regimens and prophylaxis for reducing infections in sickle cell disease. The recipient will conduct a population-based retrospective cohort study leveraging the Sickle Cell Data Collection Network (2010–2024) to assess children with sickle cell disease in Georgia,...